Valuation: Intellia Therapeutics, Inc.

Market Cap 1.72B 1.54B 1.43B 1.29B 2.42B 163B 2.45B 17.1B 6.79B 85.67B 6.46B 6.32B 272B P/E 2026 *
-3.85x
P/E 2027 * -4.65x
Enterprise Value 1.43B 1.28B 1.18B 1.07B 2B 135B 2.03B 14.17B 5.63B 71.02B 5.35B 5.24B 225B EV / Sales 2026 *
27.5x
EV / Sales 2027 * 10.7x
Free-Float
96.16%
Yield 2026 *
-
Yield 2027 * -
1 day-2.69%
1 week+3.72%
Current month+1.82%
1 month+4.51%
3 months+15.09%
6 months-5.83%
Current year+36.60%
1 week 10.58
Extreme 10.58
12.31
1 month 10.58
Extreme 10.58
13.27
Current year 9.05
Extreme 9.05
18.48
1 year 7.95
Extreme 7.95
18.48
3 years 5.9
Extreme 5.9
34.87
5 years 5.9
Extreme 5.9
143.92
10 years 5.9
Extreme 5.9
202.73
Manager TitleAgeSince
Chief Executive Officer 68 01/01/2018
Director of Finance/CFO 51 22/07/2024
Chief Tech/Sci/R&D Officer 61 26/10/2026
Director TitleAgeSince
Director/Board Member 68 01/07/2014
Chairman 63 01/02/2020
Director/Board Member 74 31/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
10/2/26 A Sell

Controller/Auditor

-1,864 0.0013%
8/21/26 A Sell

Chief Executive Officer

-2,785 0.0020%
7/22/26 A Sell

Chief Financial Officer

-8,111 0.0058%
Change 5-day change 1-year change 3-year change Capi.($)
+9.06%+3.72%-16.97%-46.98% 1.72B
-3.10%-4.19%+32.67%+59.47% 63.48B
+0.36%-0.15%+10.25%+79.56% 54.55B
-1.26%+0.87%+10.31%+101.93% 53.59B
-0.75%+1.38%+24.89%+50.91% 44.75B
-1.30%-4.80%+16.05%+114.76% 41.62B
+1.26%-5.26%+221.12%+900.64% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+0.03%+14.69%+60.91%+50.93% 26.7B
+3.72%-6.23%+26.01%-8.28% 23.36B
Average -0.45%-0.70%+39.62%+134.76% 38.22B
Weighted average by Cap. -0.59%-1.25%+42.80%+154.69%

Financials

2026 *2027 *
Net sales 51.88M 46.56M 42.99M 38.99M 72.87M 4.93B 73.76M 515M 205M 2.58B 195M 191M 8.19B 126M 113M 105M 94.88M 177M 11.99B 180M 1.25B 498M 6.29B 474M 464M 19.93B
Net income -420M -377M -348M -316M -590M -39.9B -597M -4.17B -1.66B -20.91B -1.58B -1.54B -66.31B -374M -336M -310M -281M -525M -35.52B -532M -3.72B -1.48B -18.62B -1.4B -1.37B -59.04B
Net Debt -294M -264M -244M -221M -413M -27.95B -418M -2.92B -1.16B -14.65B -1.1B -1.08B -46.46B -366M -328M -303M -275M -514M -34.75B -520M -3.63B -1.44B -18.21B -1.37B -1.34B -57.76B
Projected Income Statement - Annual - Intellia Therapeutics, Inc.
Logo Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
Employees
377
Date Price Change Volume
27/10/26 $12.28 +9.06% 3,851,011
26/10/26 $11.26 +0.45% 2,064,596
23/10/26 $11.21 +0.45% 3,566,569
22/10/26 $11.16 -4.21% 3,651,233
21/10/26 $11.65 -1.60% 2,828,931
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Intellia Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
12.28USD
Average target price
23.11USD
Spread / Average Target
+88.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Intellia Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. NTLA Stock